RxDoctor Payments Data

Frederick Sauerburger, MD

Ophthalmology · Waldorf, MDNPI 1538163514

Payments from drug & device makers

$979in general payments, 2019–2025

Across 28 payments — averaging $34.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$252
  • Carl Zeiss Meditec, Inc.$243
  • AbbVie$135
  • Tarsus Pharmaceuticals, Inc.$99
  • Sun Pharmaceutical Industries Inc.$54
  • Alcon$40
  • plus $158 from 7 others

What the payments were for

  • Food & beverage$89691%
  • Gifts$849%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$979 in reported general payments places this provider in the 45th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$233,602
Medicare patients
804
Services billed
1,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine21$30,554
ProlensaBromfenac Sodium40$14,049
Travoprost46$11,213
LumiganBimatoprost23$10,145
CombiganBrimonidine Tartrate/Timolol27$7,086
DurezolDifluprednate24$5,077
Bromfenac Sodium21$3,465
SimbrinzaBrinzolamide/Brimonidine Tart13$2,629
Cosopt PfDorzolamide/Timolol/Pf11$2,093
Prednisolone Acetate62$1,843
Latanoprost70$1,354
MoxifloxacinMoxifloxacin Hcl59$1,332
Difluprednate13$1,174
Ketorolac Tromethamine45$830
Tobramycin-DexamethasoneTobramycin/Dexamethasone16$698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$135$47,78671 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$252$14,04940 claims
NovartisDurezol$18$5,07724 claims
AlconSimbrinza$40$2,62913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Waldorf

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →